公开(公告)号：US20220289759A1

公开(公告)日：2022-09-15

申请号：US17636116

申请日：2020-08-22

Applicant: DEVELOPMENT CENTER FOR BIOTECHNOLOGY

Inventor： Shao-Zheng PENG ,  Chu-Bin LIAO ,  Hung-Jyun HUANG ,  Yuan-Ting CHO ,  Yi-Mei CHANG ,  Yu-Chih PAN

IPC: C07D495/04 ,  C07D519/00 ,  A61P35/00

Abstract: A compound, which can act as inhibitors of protein kinases, especially Class III RTKs such as FLT3, PDGFRα, c-KIT and/or CSF-1R kinases, for the treatments of diseases or disorders mediated by such kinases, has a structure of formula (I): or a stereoisomer, a tautomer, a pharmaceutically acceptable salt, a binder of a Proteolysis-Targeting Chimera (PROTAC) thereof. The compound can be used in the treatments of diseases or conditions mediated by FLT3, PDGFR, c-KIT, and/or CSF-1R kinases, or mediated by a mutant kinase of FLT3, PDGFR, c-KIT, and/or CSF-1R kinases. Such diseases or conditions may include cancers, autoimmune diseases, and bone resorptive diseases.

公开(公告)号：US20210009597A1

公开(公告)日：2021-01-14

申请号：US16958721

申请日：2018-12-26

Applicant: DEVELOPMENT CENTER FOR BIOTECHNOLOGY

Inventor： Shih-Chieh YEN ,  Chu-Bin LIAO ,  Hui-Chen WANG ,  Po-Ting CHEN ,  Yu-Chih PAN ,  Tsung-Hui LI ,  Bo-Rong CHEN ,  Shian-Yi CHIOU

IPC: C07D487/04 ,  A61P35/00

Abstract: Disclosed are compounds of formula (I) below and tautomers, stereoisomers, isotopologues, or pharmaceutically acceptable salts thereof: in which each of variables R1, ring A, L, W, V, and G is defined herein. Also disclosed are a method for treating disease or disorder mediated by Tyro3, Axl, and/or Mer kinase with a compound of formula (I) or a tautomer, stereoisomer, isotopologue, or salt thereof and a pharmaceutical composition containing same.